Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05709314Phase 2Recruiting

A Study of AMDX-2011P in Participants With CAA

Role: lead

NCT06514001Phase 2Recruiting

A Study of AMDX-2011P in Participants With Alzheimer's Disease

Role: lead

NCT05542576Phase 1Completed

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

Role: lead

NCT06223048Phase 2Recruiting

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Role: lead

All 4 trials loaded